MORF - Eli Lilly's First Biotech Deal Of 2024 Buys Chronic Disease Player Morphic For $3.2B | Benzinga
Monday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion.
Morphic is a biopharmaceutical company developing a portfolio of oral integrin therapies for chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform.
Morphic’s lead program, MORF-057, is a selective oral small molecule inhibitor of ?4?7 integrin for inflammatory bowel disease (IBD) that can potentially improve outcomes and expand treatment options for patients.
MORF-057 is being evaluated in two Phase 2 studies ...